Novavax's GAAP loss for 2021 was $1.744 billion, up 4.2 times from $0.418 billion in the previous year. Revenue increased 2.4 times to $1.146 billion from $0.476 billion a year earlier.
Novavax's GAAP loss for 2021 was $1.744 billion, up 4.2 times from $0.418 billion in the previous year. Revenue increased 2.4 times to $1.146 billion from $0.476 billion a year earlier. 
ir.novavax.com
English (US) 